Effect of early intensive multifactorial therapy compared with routine care on self-reported health status, general well-being, diabetes-specific quality of life and treatment satisfaction in screen-detected type 2 diabetes mellitus patients (ADDITION-Eu

详细信息    查看全文

• 作者：Maureen Van den Donk ; Simon J. Griffin ; Rebecca K. Stellato…
• 关键词：Diabetes screening ; Health status ; Intensive treatment ; Patient ; reported outcome measures ; Primary care ; Quality of life ; Treatment satisfaction ; Type 2 diabetes mellitus
• 刊名：Diabetologia
• 出版年：2013
• 出版时间：November 2013
• 年：2013
• 卷：56
• 期：11
• 页码：2367-2377
• 全文大小：280KB
• 参考文献：1. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O (2003) Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348:383-93 CrossRef
  2. Gaede P, Lund-Andersen H, Parving HH, Pedersen O (2008) Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358:580-91 CrossRef
  3. Griffin SJ, Borch-Johnsen K, Davies MJ et al (2011) Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. Lancet 378:156-67 CrossRef
  4. Peyrot M, Rubin RR, Lauritzen T, Snoek FJ, Matthews DR, Skovlund SE (2005) Psychosocial problems and barriers to improved diabetes management: results of the Cross-National Diabetes Attitudes, Wishes and Needs (DAWN) Study. Diabet Med 22:1379-385 CrossRef
  5. Black N (2013) Patient reported outcome measures could help transform healthcare. BMJ 346:f167 CrossRef
  6. Darzi A (2008) Quality and the NHS next stage review. Lancet 371:1563-564 CrossRef
  7. UK Prospective Diabetes Study Group (1999) Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). Diabetes Care 22:1125-136 CrossRef
  8. Anderson RT, Narayan KM, Feeney P et al (2011) Effect of intensive glycemic lowering on health-related quality of life in type 2 diabetes: ACCORD trial. Diabetes Care 34:807-12 CrossRef
  9. Echouffo-Tcheugui JB, Simmons RK, Williams KM et al (2009) The ADDITION-Cambridge trial protocol: a cluster-randomised controlled trial of screening for type 2 diabetes and intensive treatment for screen-detected patients. BMC Public Health 9:136 CrossRef
  10. Janssen PG, Gorter KJ, Stolk RP, Rutten GE (2009) Randomised controlled trial of intensive multifactorial treatment for cardiovascular risk in patients with screen-detected type 2 diabetes: 1-year data from the ADDITION Netherlands study. Br J Gen Pract 59:43-8 CrossRef
  11. Lauritzen T, Griffin S, Borch-Johnsen K, Wareham NJ, Wolffenbuttel BH, Rutten G (2000) The ADDITION study: proposed trial of the cost-effectiveness of an intensive multifactorial intervention on morbidity and mortality among people with type 2 diabetes detected by screening. Int J Obes Relat Metab Disord 24(Suppl 3):S6–S11 CrossRef
  12. Webb DR, Khunti K, Srinivasan B et al (2010) Rationale and design of the ADDITION-Leicester study, a systematic screening programme and randomised controlled trial of multi-factorial cardiovascular risk intervention in people with type 2 diabetes mellitus detected by screening. Trials 11:16 CrossRef
  13. Sandbaek A, Griffin SJ, Rutten G et al (2008) Stepwise screening for diabetes identifies people with high but modifiable coronary heart disease risk. The ADDITION study. Diabetologia 51:1127-134 CrossRef
  14. Van den Donk M, Sandbaek A, Borch-Johnsen K et al (2011) Screening for type 2 diabetes. Lessons from the / ADDITION-Europe study. Diabet Med 28:1416-424 CrossRef
  15. Alberti KGMM, Zimmet PZ (1999) Definition, diagnosis and classification of diabetes mellitus and its complications. World Health Organization, Geneva
  16. Collins R, Armitage J, Parish S, Sleigh P, Peto R (2003) MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361:2005-016 CrossRef
  17. McIntosh A, Hutchinson A, Home PD et al (2001) Royal College of General Practitioners. Clinical guidelines and evidence review for type 2 diabetes: management of blood glucose. University of Sheffield, Sheffield, UK
  18. Royal College of General Practitioners in Denmark (1999) Type 2-diabetes in general practice—diagnosis and treatment. Royal College of General Practitioners, Copenhagen, Denmark
  19. Rutten GEHM, Verhoeven S, Heine RJ et al (1999) Dutch College of General Practitioners. Practice guidelines: diabetes mellitus type 2. Huisarts Wetenschap 42:67-4
  20. Ware JE Jr, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30:473-83 CrossRef
  21. Dolan P (1997) Modeling valuations for EuroQol health states. Med Care 35:1095-108 CrossRef
  22. Brooks R (1996) EuroQol: the current state of play. Health Policy 37:53-2 CrossRef
  23. Pouwer F, van der Ploeg HM, Ader HJ, Heine RJ, Snoek FJ (1999) The 12-item well-being questionnaire. An evaluation of its validity and reliability in Dutch people with diabetes. Diabetes Care 22:2004-010 CrossRef
  24. Pouwer F, Snoek FJ, van der Ploeg HM, Ader HJ, Heine RJ (2000) The well-being questionnaire: evidence for a three-factor structure with 12 items (W-BQ12). Psychol Med 30:455-62 CrossRef
  25. Bradley C, Todd C, Gorton T, Symonds E, Martin A, Plowright R (1999) The development of an individualized questionnaire measure of perceived impact of diabetes on quality of life: the ADDQoL. Qual Life Res 8:79-1 CrossRef
  26. Bradley C (1994) Diabetes treatment satisfaction questionnaire. In: Bradley C (ed) Handbook of psychology and diabetes: a guide to psychological measurement in diabetes research and practice. Harwood Academic, Chur, pp 111-32
  27. Donders AR, van der Heijden GJ, Stijnen T, Moons KG (2006) Review: a gentle introduction to imputation of missing values. J Clin Epidemiol 59:1087-091 inepi.2006.01.014">CrossRef
  28. Webb DR, Khunti K, Gray LJ et al (2012) Intensive multifactorial intervention improves modelled coronary heart disease risk in screen-detected type 2 diabetes mellitus: a cluster randomized controlled trial. Diabet Med 29:531-40 CrossRef
  29. Van den Donk M, Gorter KJ, Rutten GE (2010) No negative effects of a multi-factorial, intensified treatment on self-reported health status, treatment satisfaction, and diabetes-related distress in screen-detected type 2 diabetes patients. The ADDITION-Netherlands study. Qual Life Res 19:509-13 CrossRef
  30. Davies MJ, Heller S, Skinner TC et al (2008) Effectiveness of the Diabetes Education and Self Management for Ongoing and Newly Diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cluster randomised controlled trial. BMJ 336:491-95 CrossRef
  31. Redekop WK, Koopmanschap MA, Stolk RP, Rutten GE, Wolffenbuttel BH, Niessen LW (2002) Health-related quality of life and treatment satisfaction in Dutch patients with type 2 diabetes. Diabetes Care 25:458-63 CrossRef
  32. Cleveringa FG, Minkman MH, Gorter KJ, van den Donk M, Rutten GE (2010) Diabetes Care Protocol: effects on patient-important outcomes. A cluster randomized, non-inferiority trial in primary care. Diabet Med 27:442-50 CrossRef
  
• 作者单位：Maureen Van den Donk (1)
  Simon J. Griffin (2)
  Rebecca K. Stellato (1)
  Rebecca K. Simmons (2)
  Annelli Sandb?k (3)
  Torsten Lauritzen (3)
  Kamlesh Khunti (4)
  Melanie J. Davies (4)
  Knut Borch-Johnsen (5)
  Nicholas J. Wareham (2)
  Guy E. H. M. Rutten (1)
  
  1. Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, PO Box 85500, 3508 GA, Utrecht, the Netherlands
  2. MRC Epidemiology Unit, University of Cambridge, Cambridge, UK
  3. Department of Public Health, Section of General Practice, University of ?rhus, ?rhus, Denmark
  4. Diabetes Research Unit, University of Leicester, Leicester, UK
  5. Holbaek Hospital, Holbaek, Denmark
  
• ISSN：1432-0428

文摘

Aims/hypothesis The study aimed to examine the effects of intensive treatment (IT) vs routine care (RC) on patient-reported outcomes after 5?years in screen-detected diabetic patients. Methods In a pragmatic, cluster-randomised, parallel-group trial, 343 general practices in Denmark, Cambridge and Leicester (UK) and the Netherlands were randomised to screening for type 2 diabetes mellitus plus IT of multiple risk factors in people 40-9?years without known diabetes (n--,678 patients) or screening plus RC (n--,379 patients). Practices were randomised in a 1:1 ratio according to a computer-generated list. Diabetes mellitus was diagnosed according to WHO criteria. Exclusions were: life expectancy <1?year, housebound, pregnant or lactating, or psychological or psychiatric problems. Treatment targets for IT were: HbA1c <7.0% (53?mmol/mol), BP ?35/85?mmHg, cholesterol <5?mmol/l in the absence of a history of coronary heart disease and <4.5?mmol/l in patients with cardiovascular (CV) disease; prescription of aspirin to people taking antihypertensive medication and, in cases of CV disease or BP >120/80?mmHg, ACE inhibitors were recommended. After 2003, the treatment algorithm recommended statins to all patients with cholesterol of ?.5?mmol/l. Outcome measures were: health status (Euroqol 5 Dimensions [EQ-5D]) at baseline and at follow-up; and health status (36-item Short Form Health Survey [SF-36] and Euroquol Visual Analogue Scale [EQ-VAS]), well-being (12-item Short Form of the Well-Being Questionnaire), diabetes-specific quality of life (Audit of Diabetes-Dependent Quality of Life) and satisfaction with diabetes treatment (Diabetes Treatment Satisfaction Questionnaire) at follow-up. At baseline, standardised self-report questionnaires were used to collect information. Questionnaires were completed at the same health assessment visit as the anthropometric and biochemical measurements. The patients and the staff assessing the outcomes were unaware of the group assignments. Participants were followed for a mean of 5.7?years. Outcome data were available for 1,250 participants in the intensive treatment group (74%) and 967 participants in the routine care group (70%). The estimated differences in means from the four centres were pooled using random effects meta-analysis. Baseline EQ-5D level was used as a covariate in all analyses. Results EQ-5D values did not change between diagnosis and follow-up, with a median (interquartile range) of 0.85 (0.73-.00) at baseline and 0.85 (0.73-.00) at 5?year follow-up. Health status, well-being, diabetes-specific quality of life and treatment satisfaction did not differ between the intensive treatment and routine care groups. There was some heterogeneity between centres (I 2 being between 13% [SF-36 physical functioning] and 73% [EQ-VAS]). Conclusions/interpretation There were no differences in health status, well-being, quality of life and treatment satisfaction between screen-detected type 2 diabetes mellitus patients receiving intensive treatment and those receiving routine care. These results suggest that intensive treatment does not adversely affect patient-reported outcomes. Trial registration number ClinicalTrials.gov NCT00237549 Funding ADDITION-Denmark was supported by the National Health Services, the Danish Council for Strategic Research, the Danish Research Foundation for General Practice, Novo Nordisk Foundation, the Danish Centre for Evaluation and Health Technology Assessment, the Diabetes Fund of the National Board of Health, the Danish Medical Research Council and the Aarhus University Research Foundation. In addition, unrestricted grants from pharmaceutical companies were received. ADDITION-Cambridge was supported by the Wellcome Trust, the Medical Research Council, the NIHR Health Technology Assessment Programme, National Health Service R&D support funding and the National Institute for Health Research. SJG received support from the Department of Health NIHR grant funding scheme. ADDITION-Leicester was supported by Department of Health, the NIHR Health Technology Assessment Programme, National Health Service R&D support funding and the National Institute for Health Research. ADDITION-Netherlands was supported by unrestricted grants from Novo Nordisk, Glaxo Smith Kline and Merck, and by the Julius Center for Health Sciences and Primary Care, University Medical Center, Utrecht.